Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.57 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.57 |
| ▸ | CDK2 | P24941 | 3/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | NSD3 | Q9BZ95 | 5/20 | 0.40 |
| ▸ | NSD2 | O96028 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385552 | 0.86 | HSP90AB1 (0.49) | HSP90AA1HSP90AB1 | |
| SCHEMBL27871148 | 0.84 | CDK1 (0.56) | CDK1CCNB1CCNE1CDK2FGFR1 | |
| SCHEMBL28301970 | 0.82 | CDK1 (0.65) | CDK1CCNB1CCNE1CDK2FGFR1 | |
| SCHEMBL217726 | 0.82 | POLB (0.45) | CDK1CCNB1CCNE1CDK2FGFR1 | |
| SCHEMBL382916 | 0.81 | FGFR1 (0.66) | FGFR1SLC22A6NSD3NSD2LMNA | |
| Pmedap SCHEMBL29571667 | 0.80 | FGFR1 (0.72) | CDK1CCNB1CCNE1CDK2FGFR1 | |
| Pmedap SCHEMBL215611 | 0.80 | FGFR1 (0.72) | CDK1CCNB1CCNE1CDK2FGFR1 | |
| SCHEMBL27871143 | 0.79 | CDK1 (0.53) | CDK1CCNB1CCNE1CDK2FGFR1 | |
| SCHEMBL7591540 | 0.79 | SLC29A1 (0.63) | CDK1CCNB1CCNE1CDK2POLB | |
| SCHEMBL4022228 | 0.79 | CCNE1 (0.68) | CDK1CCNB1CCNE1CDK2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230110614-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | ATOSSA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | claimed |
| EP-4125936-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | Atossa Therapeutics, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2021194890-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | ATOSSA THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | claimed |
| EP-2223927-A2 | Cyclic phosphonic acid based prodrugs of PMEA and its analogues | Metabasis Therapeutics, Inc. (US) | 2010-09-01 | — | — | EP | claimed |
| EP-1532157-A4 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | METABASIS THERAPEUTICS INC (US) | 2009-02-25 | — | — | EP | claimed |
| US-7205404-B1 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | claimed |
| EP-1165570-B9 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1165570-B1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2006-08-23 | — | — | EP | claimed |
| EP-1532157-A2 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | Metabasis Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | claimed |
| WO-2004037161-A2 | CYCLIC PRODRUGS OF PMEA ONE OF ITS ANALOGUES | METABASIS THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. | 2003-12-11 | — | — | US | claimed |
| US-6060463-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | Freeman, William (US) | 2000-05-09 | — | — | US | claimed |
| US-5869468-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | FREEMAN WILLIAM R (US) | 1999-02-09 | — | — | US | claimed |
| EP-0754046-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN, William R. (US) | 1997-01-22 | — | — | EP | claimed |
| WO-1995026734-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN WILLIAM R (US) | 1995-10-12 | — | — | WO | claimed |
| US-12576103-B2 | Heparin and N-acetylcysteine for the treatment of lung injury | ATOSSA THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20240360163-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2024-10-31 | — | — | US | disclosed |
| US-5514798-A | REACTION OF CYCLIC CARBONATE WITH PURINE OR PYRIMIDINE BASE IN SOLVENT AND CRYSTALLIZATION | GILEAD SCIENCES, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| WO-1995026734-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN WILLIAM R (US) | 1995-10-12 | — | — | WO | disclosed |
| WO-1994014981-A1 | TREATMENT OF VIRAL INFECTIONS | CHEN ROLLAND (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360163-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | CDK1 1325/4885CCNB1 1596/4885CCNE1 958/4885 |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | MTAP, PNP, MPO | CDK1 792/4885CCNB1 543/4885CCNE1 979/4885 |
| US-12576103-B2 | Heparin and N-acetylcysteine for the treatment of lung injury | SERPINC1, TXNRD2, TXN | CDK1 1494/4885CCNB1 4158/4885CCNE1 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.